Previous close | 146.72 |
Open | 146.70 |
Bid | 144.98 x 100 |
Ask | 145.63 x 200 |
Day's range | 145.19 - 147.49 |
52-week range | 143.52 - 218.88 |
Volume | |
Avg. volume | 853,791 |
Market cap | 18.376B |
Beta (5Y monthly) | 0.40 |
PE ratio (TTM) | N/A |
EPS (TTM) | -3.52 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 222.68 |
Alnylam Pharmaceuticals (ALNY) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
CAMBRIDGE, Mass., April 07, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced positive results from the KARDIA-2 Phase 2 study evaluating the efficacy and safety of a single subcutaneous dose of zilebesiran when added to one of three standard of care antihypertensives including a thiazide-like diuretic (indapamide), calcium channel blocker (amlodipine) or angiotensin receptor blocker (olmesartan). Zilebesiran is an investigational RNAi the
It hasn't been the best quarter for Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) shareholders, since the share price...